Modular Medical, Inc.

Certification Represents Another Milestone Toward CE Mark Submission for Pivot

Game-Based Education Tools Designed to Help Improve Patient Familiarity with Pump Therapy and Support Healthcare Providers in Identifying Candidates for Pump Adoption

Clearance Covers Software Enhancements for Greater Patient Flexibility and Pivot Customization

First Phase of Strategic Rollout Targets Markets with Leading Insulin Pump Prescribers and Strong New Pump Adoption. Inizio will Provide Commercialization Expertise to Accelerate Awareness and Adoption of the Pivot Pump.

- Council to Provide Strategic Clinical Guidance on Commercialization, Patient Identification, Workflow Integration, and Evidence Generation

• Pilot Combines Clinician Guided Phenotypes with IMO Health's Unique Terminology Identifiers to Help Clinicians Easily Identify Patients Most Likely to Benefit from Pivot Insulin Pump Therapy

• Advancing Towards Fourth Quarter Commercial Launch of Pivot Pump

Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot

97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes

Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump

Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026

Submission Covers Software Enhancements for Patient Flexibility and Customization of Pivot

First Patients Began Device Training and Insulin Delivery Today, Marking Transition to a Commercial Company

Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar Market

Pivot starter kits are now shipping to multiple endocrinology practices

• The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April

• Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market

• Commercial expansion activities are expected to begin in Q4 2026

Initial patients expected in June 2026

• Meet with Modular Medical CEO Jeb Besser

• Discover Modular Medical's Pivot, the first FDA-cleared, two-part tubeless patch pump featuring a removable 3 mL reservoir, disposable battery, smartphone connectivity for bolus and monitoring, and true electronic accuracy without tubes or constant wear and its associated commercial & manufacturing timeline.

First Removable 2-Part Design Targets $3 Billion "Almost-Pumper" Market with Expected Q2 2026 initial deployment.

Key Milestones & Investment Highlights:

• FDA 510(k) Clearance Achieved: Pivot^™ pump now cleared for commercial sale in the U.S. - major de-risking event unlocking revenue path.

• First-in-Class Removable Tubeless Patch Pump: 3 mL detachable reservoir; no battery recharging required; removable for showering, sports or discretion; quick bolus button without a separate controller.

• Targets Massive Underserved Market: ~70% of insulin-dependent adults remain on multiple daily injections (MDI) due to complexity, cumbersomeness and cost - Pivot addresses the "3 Cs" for "almost-pumpers" with its 2-part reusable pump.

• Manufacturing Readiness: Production validation lots well underway; initial capacity supports ~6,000 users with scalable low-cost platform enabling a rapid production ramp-up.

• Commercial Timeline: Initial customers expected by end of Q2 2026; software enhancements (e.g., variable bolus, improved alarms, ACE/AID compatibility) in development; CE Mark targeted Q4 2026/Q1 2027.

Targeting Q1 2026 Launch, Subject to FDA Clearance

Key Highlights:

• Cartridge & Infusion Set Lots in Production: Validation production lots now being produced for launch, derisking commercial-scale production.

• First Removable Tubeless Patch Pump: Pivot targets underserved "almost-pumpers" - adults with diabetes hesitant to move from multiple daily injections (MDI) due to cost and complexity - representing a significant portion of the growing ~$8 billion global insulin pump market.

• Affordable, User-Friendly Design: A full 3ml removable cartridge and pump with a simple interface expands access for millions managing diabetes with MDI by providing significant clinical therapy improvement

Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump

- Aims to Improve Patient and Clinician Experience for the Care of Diabetes

Key Highlights:

• Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.

• Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, user-friendly, easy-to-learn design.

High-Volume Manufacturing Readiness: Modular Medical's scalable platform positions it to target a significant share of the insulin pump market.

Key Highlights:

• Pivot continues to progress toward CE Mark certification in 2026

• Stage 1 ISO Audit completed with Stage 2 planned for 1H2026

-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps

-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump

- Use of MODD1 on clinicians with Type 1 diabetes

-More than 6,000 MODD1 cartridges produced

- Conversion to Pivot-ready manufacturing in preparation for product launch in 1Q26

-Debuting a "coming soon" campaign for tubeless Pivot patch pump

- Expects special 510(k) filing for Pivot product in October

- Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game

- Use of MODD1 on clinician with Type 1 diabetes

- Modular Medical intends to deploy the MODD1 on a larger number of clinicians in mid August

-Line has been in production at risk since early July
- Production to continue until late August when conversion to Pivot manufacturing will begin

- Engaged BSI Group to start the process of obtaining regulatory clearance of the MODD1, next-generation insulin pump for the European market

- Targeting Q1 2026 for expected clearance of the MODD1 in the E.U.

-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements

-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough